148
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects

, , , , , , & show all
Pages 991-997 | Published online: 03 Apr 2019

References

  • Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18-e209.
  • Yeon OK, Yun JHS. The Statics of Deaths in 2013. Daejeon, Republic of Korea: The Korean National Statistical Office(KNSO); 2013.
  • Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination. Am J Cardiovasc Drug. 2009;9(5):309–330. doi:10.2165/11201120-000000000-00000
  • Schwocho LR, Masonson HN. Pharmacokinetics of CS‐866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41(5):515–527.11361048
  • Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. Clin Ther. 2007;29(10):2194–2203. doi:10.1016/j.clinthera.2007.10.00518042475
  • Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365(9457):434–441. doi:10.1016/S0140-6736(05)70240-315680460
  • Dezii C. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managed Care (Langhorne, Pa). 2000;9(9 Suppl):2–6.
  • Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018;15(6):e1002584. doi:10.1371/journal.pmed.100259329889841
  • Lee S-Y, Kim J-R, Jung JA, Huh W, Bahng MY, Ko J-W. Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects. Drug Des Devel Ther. 2015;9:2811. doi:10.2147/DDDT.S82820
  • Oh MJ, Hwang HH, Kim HG, et al. Bioequivalence study of a new fixed-dose combination tablet containing S-amlodipine nicotinate and olmesartan medoxomil in healthy Korean male subjects. Clin Ther. 2017;39(7):1371–1379. doi:10.1016/j.clinthera.2017.05.35528625505
  • Park J-Y, Kim K-A, Lee G-S, et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. Clin Ther. 2004;26(5):715–723.15220015
  • Rohatagi S, Lee J, Shenouda M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed‐dose combination. J Clin Pharmacol. 2008;48(11):1309–1322. doi:10.1177/009127000832217618974285
  • Collaboration PS. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. doi:10.1016/S0140-6736(02)11911-812493255
  • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003;289(19):2560–2571. doi:10.1001/jama.289.19.256012748199
  • Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–289. doi:10.1016/j.jacc.2017.03.01128315732
  • The Statistics of 5th Korea National Health and Nutrition Examination Survey (KNHANES V-S) in 2011. Korea Centers for Disease Control and Prevention; 2011.
  • Mokrini F, Waeyenberge L, Viaene N, Moens M The Statistics of the 8th Korea Youth Risk Behavior Web-based Survey(KYRBWS) in 2012. Korea Centers for Disease Control and Prevention; 2012. doi:10.1094/PDIS-11-11-0999-PDN
  • Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Heart Dis. 2004;2:3.
  • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy33930165516